Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with
Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily
infusions of SoluMedrol. Main objective is to assess the occurrence of new
gadolinium-enhanced T1-weighted lesions at week 8 vs week 1 after treatment.